18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: A systematic review

Clinical Imaging

Volumn 36, Issue 3, 2012, Pages 167-175

  Treglia, Giorgio ^a   Mirk, Paoletta ^a   Stefanelli, Antonella ^a   Rufini, Vittoria ^a   Giordano, Alessandro ^a   Bonomo, Lorenzo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Gastrointestinal stromal tumors; PET CT; Positron emission tomography; Treatment response; Tyrosine kinase inhibitors

Indexed keywords

CLINICAL OUTCOME; F-FLUORODEOXYGLUCOSE; GASTROINTESTINAL STROMAL TUMORS; IMATINIB; LITERATURE SEARCH; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TYROSINE KINASE INHIBITOR;

AMINO ACIDS; POSITRON EMISSION TOMOGRAPHY; TUMORS;

PATIENT TREATMENT;

DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IMATINIB; MASITINIB; MOTESANIB; SUNITINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG SCREENING; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; ISOTOPE TRACING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; GASTROINTESTINAL TUMOR; META ANALYSIS; PREVALENCE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; PYRIMIDINES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84860283078     PISSN: 08997071     EISSN: 18734499     Source Type: Journal    
DOI: 10.1016/j.clinimag.2011.08.012     Document Type: Review

References (37)

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-465.
2. Miettinen M, Lasota J Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001, 438:1-12.
3. Connolly EM, Gaffney E, Reynolds JV Gastrointestinal stromal tumours. Br J Surg 2003, 90:1178-1186.
4. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002, 3:655-664.
5. Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. RadioGraphics 2003, 23:283-304.
6. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
7. DeMatteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33:466-477.
8. Miettinen M, Lasota J Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
9. Verweij J, Casali PG, Zalcberg J, et al. Progression free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
10. Kochhar R, Manoharan P, Leahy M, Taylor MB Imaging in gastrointestinal stromal tumours: current status and future directions. Clin Radiol 2010, 65:584-592.
11. Basu S PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications. Eur J Nucl Med Mol Imaging 2010, 37:1255-1258.
12. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
13. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
16. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003, 39:2012-2020.
17. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004, 45:17-21.
18. Jager PL, Gietema JA, van der Graaf WT Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004, 25:433-438.
19. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004, 45:357-365.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981, 47:207-214.
21. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004, 183:1619-1628.
22. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
23. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005, 32:153-162.
24. Goldstein D, Tan BS, Rossleigh M, et al. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response-an AGITG study. Oncology 2005, 69:326-332.
25. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 2007, 189:W324-W330.
26. Green S, Weiss GR Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992, 10:239-253.
27. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16:910-919.
28. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-4774.
29. Van Glabbeke M, Verweij AM, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005, 23:5795-5803.
30. 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009, 27:439-445.
31. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009, 15:5902-5909.
32. Maurel J, Martins AS, Poveda A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010, 116:3692-3701.
33. Fuster D, Ayuso JR, Poveda A, et al. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Q J Nucl Med Mol Imaging 2010, Dec 9. [Epub ahead of print].
34. Le Cesne A, Blay JY, Bui BN, et al. Phase II study of oral masitinib mesylate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010, 46:1344-1351.
35. Benjamin RS, Schöffski P, Hartmann JT, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011, 68:69-77.
36. Lassau N, Chami L, Koscielny S, et al. Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs 2010, Dec 7. [Epub ahead of print]. DOI:10.1007/s10637-010-9592-2.
37. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566-578.